For research and laboratory use only. Not for human or animal consumption. Not intended for diagnostic, therapeutic, or clinical use.
CJC-1295 (No DAC) + Ipamorelin
CJC-1295 (No DAC) + Ipamorelin from Primeva Labs is offered strictly for research use only. Each order includes batch-specific CoA documentation, quality verification, and secure online ordering. Not for human or animal consumption.
Primeva Labs supplies materials strictly for laboratory and research use. Create a complimentary research account to view current pricing, availability, and ordering.
By creating an account you confirm you are 21+, agree to the Terms & Research-Use Disclaimer, and acknowledge these products are sold strictly for research use — not for human or animal consumption.
What Is CJC-1295 (No DAC) + Ipamorelin?
This co-lyophilized blend pairs the GHRH analog CJC-1295 (No DAC) with the selective secretagogue Ipamorelin — two compounds frequently studied together for complementary GH-axis signaling.
- Combines a GHRH-receptor analog with a ghrelin-receptor secretagogue
- Two distinct receptors studied for additive growth-hormone signaling
- Per-component assay reported on a batch-specific certificate
- Supplied strictly as a research-grade reference material
Research Applications
Combined GH-axis research
Studied as a pairing acting on two distinct GH-release pathways.
Synergy studies
Examined for additive or synergistic GH release versus either compound alone.
Pulsatile-signaling research
Used to study coordinated GHRH + secretagogue stimulation of somatotrophs.
Endocrine-model research
Investigated as a combined secretagogue tool in endocrine-pathway studies.
Proposed Mechanisms
Dual-receptor stimulation
CJC-1295 activates the GHRH receptor while Ipamorelin activates the ghrelin (GHS) receptor.
Complementary pathways
Combined cAMP (GHRH) and PLC/calcium (GHS) signaling is studied for additive GH output.
Selective profile
Ipamorelin contributes GH release without significant cortisol/prolactin effects.
IGF-1 axis
Downstream GH release is studied for its influence on the IGF-1 pathway.
Mechanisms described above are drawn from preclinical (cell and animal) research and, where noted, early clinical literature. They are provided for educational context and should not be read as clinical or therapeutic claims.
